By Jennifer C. Miller, PhD, Vice President of Clinical & Scientific Operations, Galaxy Diagnostics
Summary: Babesia is an intraerythrocytic parasite that has become one of the most persistent diagnostic blind spots in tick-borne medicine. Despite growing clinical recognition, standard testing methods frequently fail to detect Babesia in chronic presentations, where parasitemia is low, symptoms overlap with other vector-borne infections, and human-specific research remains limited. This post, drawn from a Galaxy Diagnostics clinical webinar presented by Dr. Jennifer Miller, explains why the diagnostic picture for Babesia is so often incomplete: how the organism’s biology makes it difficult to see, why different testing methods produce discordant results, what the emerging prevalence data suggest about underreporting, and how a biology-informed approach to detection and interpretation can help clinicians navigate one of the most complex diagnostic challenges in vector-borne disease. Understanding why Babesia evades detection is the first step toward knowing when to test, what to test with, and how to interpret results that do not fit the textbook picture.
Table of Contents
Babesia is among the most clinically important and diagnostically elusive tick-borne pathogens in North America. Despite increasing awareness of babesiosis beyond its traditional acute presentation, the gap between clinical suspicion and laboratory confirmation remains significant. This article synthesizes key insights from a Galaxy Diagnostics clinical education webinar and outlines the biological, methodological, and interpretive factors that contribute to the diagnostic challenge.
The Black Box: Why Babesia Does Not Follow the Textbook
The term “black box” describes a clinical scenario that many providers working with complex, chronic patients will recognize immediately. Clinical suspicion is present. Testing has been performed. And yet the results do not fully explain what the patient is experiencing. With Babesia, this disconnect happens because four distinct layers frequently fail to align: the clinical presentation, the pathogen’s biology, the available research, and the detection methods being utilized. When any one of these layers is incomplete or mismatched, the diagnostic picture breaks down.
Most clinicians were trained on a straightforward model of babesiosis: an acute, febrile illness with hemolysis and high parasitemia (typically attributed to Babesia microti) diagnosed by blood smear, and treated with standard antiparasitic protocols. That model is accurate for acute presentations. It is incomplete for the growing number of patients who do not fit that phenotype.
In chronic presentations, the clinical picture looks different. Patients present with persistent or relapsing fatigue, dyspnea (often described as “air hunger”), night sweats, cognitive dysfunction, and multi-system involvement. Symptom intensity fluctuates, and the observed clinical features overlap significantly with Bartonella, Borrelia, and other chronic inflammatory conditions. Because symptoms are non-specific, Babesia may be misattributed to another vector-borne infection or to a non-infectious chronic condition entirely.
Contributing factors include overlapping symptom patterns, a lack of distinguishing clinical markers, and variable provider experience with babesiosis beyond its acute form. The downstream effect is inconsistent clinical suspicion and variable diagnostic pathways. Patients get stuck: their symptoms persist despite evaluation, and their diagnostic experience may include positive serology that is difficult to interpret, negative or inconclusive molecular results, and discordant findings across methods. For the provider, this means uncertainty about next steps. For the patient, it means continuing to live without answers.
What This Means for Testing
Testing should not be treated as a simple yes-or-no endpoint when clinical suspicion remains. In complex presentations, the testing strategy should match the clinical question: prior exposure, current organism detection, or visible parasitemia. When symptoms overlap across Babesia, Bartonella, Borrelia, and other vector-borne infections, clinicians may need to revisit the differential diagnosis and select tests that address the specific clinical questions still unresolved.
The Biology Problem: Why Babesia Is Hard to See
Babesia is an intraerythrocytic parasite. Babesia infects red blood cells and replicates within circulating erythrocytes. After replication, it lyses the host cell and re-invades new red blood cells. Detection of the organism depends on parasitemia levels at the time of blood collection. This is where biology creates a significant obstacle for clinicians and laboratories alike.
In chronic presentations, parasitemia may be low or intermittent.1 The organism may not be present in detectable quantities in every blood sample. This introduces a sampling variable that is independent of the test’s performance. If the parasite burden is below the detection threshold (also known as an assay’s Limit of Detection (LOD)) at the moment blood is drawn, the test result will be negative regardless of how sensitive the assay is.
Detectability varies across testing methods, across time, and across individual blood draws. A single time-point test may miss a low-level infection that would be captured on a different day or through serial sampling.2 The clinical implication is important: a negative result does not always reflect the absence of the organism. It may instead reflect the limitations of sampling and detection.
Compounding the biology problem is a significant research gap. Babesia is well-studied in animal models, but human-specific understanding of its pathogenic behavior remains more limited than that of other major tick-borne pathogens. Funded basic research into human babesiosis in the United States is sparse. Much of what is known about Babesia virulence factors is extrapolated from comparisons to malaria rather than derived from direct study of the organism itself in human hosts.3,4
As a result, pathogenic behavior in humans is not fully defined. Clinical frameworks for diagnosing and interpreting chronic babesiosis remain incomplete. Clinicians are working with evidence that is continually evolving, but still has substantial gaps. This research deficit also creates downstream challenges for diagnostic assay development.
Serological assays, for example, require understanding of how virulence factors and surface antigens vary across Babesia species and strains. Without that knowledge, cross-reactivity between species remains difficult to assess.5,6 This includes questions about Babesia microti, Babesia duncani, Babesia odocoilei, and Babesia divergens-like organisms. It also limits the development of recombinant antigen-based assays with reliable sensitivity and specificity.
What This Means for Testing
Because Babesia parasitemia may be low or intermittent, a negative diagnostic resulting from a single blood draw should be interpreted with caution in patients whose clinical picture remains consistent with possible infection.1 Serial sampling may improve diagnostic yield when organism burden fluctuates over time. Pairing serology with molecular testing can provide complementary information when one method alone does not fully explain the clinical presentation.2,7
The Diagnostic Landscape: What Each Method Measures and Why Results Differ
Babesia testing currently includes four primary modalities, each of which detects a different biological signal. Because of that, these methods are not interchangeable, and understanding what each one measures is essential for interpreting results accurately.
Blood Smear Microscopy
Blood smear is the most established method for detecting Babesia and remains the standard approach in acute hospital settings, where parasitemia is typically high enough for direct visualization.1 A trained microscopist examines a stained thin blood film for parasites inside red blood cells, looking for the characteristic tetrad forms known as “Maltese crosses.” This method is highly specific when positive, but its sensitivity drops substantially in chronic or low-level presentations where the parasite burden may be too low to identify on a single slide.
Fluorescence In Situ Hybridization (FISH)
FISH is a direct detection method that employs fluorescently labeled probes that bind to Babesia RNA within a blood sample, allowing the organism to be visualized under a fluorescence microscope. It can detect the pathogen’s presence in select clinical scenarios. However, current commercial FISH assays for vector-borne disease are singleplex, meaning each assay targets a single organism.8 No multiplex FISH options are currently available for simultaneous multi-pathogen detection.
Serology (Indirect Immunofluorescence Assay)
Serology detects the host immune response to Babesia by measuring antibodies the patient’s immune system has produced against the parasite. A positive serological result may indicate that the patient has been exposed to Babesia at some point. However, it does not define whether the organism is currently present. Serology requires interpretation within the full clinical context, including symptom history, exposure risk, and concurrent testing results.
There are also technical challenges specific to Babesia serology.9 Because the organism grows inside red blood cells, cultivating it for whole-organism IFA slides presents scientific challenges that most bacterial pathogens do not share. Furthermore, limited understanding of how virulence factors and surface antigens vary across Babesia species creates uncertainty about the degree of species cross-reactivity between, which can affect both sensitivity and specificity.5 If the antigen used in an IFA does not closely match the species infecting the patient, the test may produce a false negative.10
PCR-Based Molecular Methods (Including Digital PCR)
Molecular methods detect Babesia nucleic acids (DNA or RNA) directly, providing a molecular signature that indicates the organism is or recently was present in the sample. Some molecular methods can also quantify the parasite burden, providing a measure of parasitemia at the time of the draw. Digital PCR (dPCR) partitions the sample into thousands of individual reactions, enabling absolute quantification and improved sensitivity for low-abundance organisms compared to standard qPCR.11 However, as with all molecular testing for low-abundance organisms, absence in a sample does not mean absence in the patient. Assay design matters: sensitivity varies by methodology (qPCR vs. dPCR), by platform, and by how the assay has been validated. Some platforms are better suited for detecting low-abundance organisms than others.
Why Discordant Results Are Expected, Not Anomalous
When providers receive conflicting results from different methods on the same patient, the explanation is often methodological rather than clinical. Different methods measure fundamentally different biological signals: parasitemia (organisms in circulation), pathogen presence (direct detection of nucleic acids), and host immune response (antibody-based detection). A patient can be seropositive and PCR-negative, or PCR-positive and seronegative, because these methods are capturing different aspects of the host-pathogen interaction.
Assay variability also plays a role. Not all assays are equally designed. Sensitivity varies by methodology, detection capability differs across platforms, and some assay designs are optimized for low-abundance organisms while others require higher parasite burdens to produce a positive result. When results are discordant, the question to ask is not only “Is the organism present?” but also “What is each method actually capable of showing me?”
What This Means for Testing
Test selection should be guided by what the clinician is trying to clarify. Blood smear may be most useful in acute settings with higher parasitemia.1 Serology can help assess immune exposure.12 Molecular methods can evaluate pathogen nucleic acids in the submitted sample.2,7,11 When results differ across methods, interpretation should focus on what each method measures rather than assuming one result invalidates another.
From Individual Cases to Population Patterns
The challenge of detecting Babesia is not limited to individual cases. Emerging data suggest that the true prevalence of babesiosis significantly exceeds what current surveillance systems capture, and that chronic presentations may be far more common than previously appreciated.
Approximately 3 million U.S. adults (roughly 1.26% of the population), have reported a Babesia diagnosis at some point.13 The CDC reports approximately 3,586 babesiosis cases annually through standard surveillance mechanisms.14 However, an analysis of insurance claims data suggests the annual burden may approach 25,000 cases, though this figure has not been independently replicated in peer-reviewed literature.15
In emerging research utilizing serial blood collections with advanced molecular detection approaches, Babesia DNA was documented in approximately 24% of patients with chronic fatigue (ME/CFS) and neurological symptoms.2 This is a notable finding that bridges individual clinical observations to broader population-level patterns and highlights the need for additional research.Additional work has also reported detection of Babesia odocoilei in symptomatic humans.6,7
The gap between clinical experience, reported cases, and research findings likely reflects differences in detection methods, differences in clinical recognition, and limitations in surveillance/reporting systems. What we detect is influenced by what we are able to measure.
What This Means for Testing
Emerging prevalence data and underreporting estimates suggest that clinicians should keep testing limitations in view when evaluating chronic or multi-system presentations.13-15 These data should not be used as stand-alone diagnostic evidence for an individual patient, but they can help explain why surveillance numbers may not reflect the full clinical burden. In patients with chronic fatigue, neurological symptoms, or possible co-infection patterns, testing strategies should account for the broader and evolving Babesia species landscape.2,6,7,12,16
How to Think About Diagnostic Strategy in Complex Cases
For clinicians navigating the diagnostic complexity of Babesia, the following considerations may help inform testing decisions and result interpretation.
Clinical framing questions to consider:
- What is this test actually measuring? Understanding whether a test detects host immune response, pathogen nucleic acids, or visible organisms is essential for interpreting what a positive or negative result means in a given clinical context.
- What can this method detect, and what can it not detect? Each method has inherent limits based on its sensitivity, the biological signal it targets, and the testing platform used. A negative result is only as informative as the method’s ability to capture the signal at the time of sampling.
- What uncertainty remains after the test result? Even after testing, clinical questions may persist. Results should be interpreted alongside the patient’s history, symptom pattern, and the known limitations of the method used.
- Has co-infection been considered? Patients presenting with chronic fatigue, neurological symptoms, and multi-system involvement may harbor more than one vector-borne pathogen. Multiplex testing that evaluates Babesia, Bartonella, and Borrelia simultaneously reflects how these infections present in clinical practice.
- Would serial sampling improve diagnostic yield? Given the fluctuating nature of Babesia parasitemia, multiple blood draws collected over time may increase the likelihood of detection. Internal data from Galaxy Diagnostics indicates that patients are approximately 2.5 times more likely to test positive on a triple-draw collection protocol than on a single draw.17 In cases where Babesia was detected across a triple draw, it was frequently positive on only one of the three draws, underscoring the value of repeated sampling.
Disclosure: BBB Direct Detect (dPCR) is a Galaxy Diagnostics Laboratory Developed Test (LDT).11 Dr. Miller is an employee of Galaxy Diagnostics and leads the development of the company’s vector-borne diagnostic assays, such as those discussed in this article. This content is intended for educational purposes only and does not constitute medical advice, treatment guidance, or diagnostic guarantees.
Galaxy Diagnostics’ BBB Direct Detect (dPCR) assay is designed with these considerations in mind, offering genus-level molecular detection across Babesia species and the option for serial triple-draw sample collection. For clinicians navigating complex cases, this biology-informed approach to molecular detection helps address the interpretive challenges discussed throughout this article. Learn more about Galaxy’s approach to tick-borne pathogen detection at the Suspected Tick-Borne Bundle page on galaxydx.com.
Frequently Asked Questions
The following questions were submitted by clinicians during a Galaxy Diagnostics educational webinar presented by Dr. Jennifer Miller, PhD. Answers have been adapted from her responses.
What is the "black box" in Babesia diagnostics?
The “black box” describes a clinical scenario in which clinical suspicion for Babesia is present and testing has been performed, but the results do not fully explain the patient’s symptoms. This happens because the clinical presentation, pathogen biology, available research, and diagnostic methods may not align, creating a gap between what the clinician observes and what the laboratory can confirm.
Do you see splenomegaly with babesiosis?
Splenomegaly is a recognized manifestation of babesiosis, and it can occur. Notably, in the cases Galaxy is currently observing through provider-shared case reviews, it is not the predominant finding. The more common presentations are chronic fatigue and tingling or neuropathy, which tend to be more atypical than what clinicians might expect from classic acute babesiosis.
What is the difference between analytical and clinical sensitivity and specificity?
Analytical sensitivity and specificity refers to how well a test performs in laboratory-simulated settings. This is measured using quality control samples spiked with organism material at known concentrations, run repeatedly to define the quantitative detection range and confirm the absence of false positives in negative samples. Clinical sensitivity and specificity, by contrast, is measured against real, well-characterized patient samples that have been vetted as true positives. Dr. Miller noted that well-characterized reference samples for Babesia do not yet exist the way they do for Lyme Borrelia, and Galaxy is actively working to build that clinical dataset through ongoing provider engagement and case studies.
What Babesia species are you finding, and in what proportions?
Galaxy’s testing is performed at the genus level, so species-level identification would require sequencing, which digital PCR does not currently allow for. Based on published work from NC State University colleagues Drs. Breitschwerdt and Maggi, Babesia species beyond Babesia microti, including Babesia odocoilei and Babesia divergens-like organisms such as MO1, have been documented in human clinical samples.18,19 Additional work has reported detection of Babesia odocoilei in symptomatic humans.6,7 These publications support the broader point that the species landscape in human infection may be wider than the standard Babesia microti framework.
Would you consider testing every chronic fatigue syndrome patient for Babesia, and if you could only use one test, which would you recommend?
If a provider suspects an infectious etiology in a chronic fatigue patient, testing for Babesia is worthwhile.2 For cost-conscious screening, serology is a reasonable first step to determine whether the patient has had prior exposure to Babesia. If serological evidence of exposure is present and clinical suspicion remains, molecular testing can then be layered in to provide additional information about current organism presence. It is also worth noting that patients are approximately 2.5 times more likely to test positive on a triple draw than on a single draw.17 The decision to test and which method to begin with should always be guided by the provider’s clinical judgment and the individual patient’s history.
Do you see bilateral or unilateral neuropathy with babesiosis?
Based on provider-reported case studies, unilateral neuropathy is observed more frequently than bilateral. It typically presents running down a full extremity such as an arm or leg, and some providers have also reported localization to the back of the head. Dr. Miller noted this reflects case study observations shared by clinicians rather than findings from a formal study.
Digital PCR works differently at a fundamental level. The sample is partitioned into tens of thousands of individual reaction chambers, each containing zero or one copy of the target DNA. Each partition is read independently as either positive or negative. The final count of positive partitions is used to calculate the absolute number of target molecules present, with no reference standard required and no estimation involved. This absolute quantification approach means dPCR can detect and count target DNA even at extremely low copy numbers that fall well below the detection threshold of standard qPCR. In the context of Bartonella, where bacterial burden in chronic infection may be just a handful of organisms per milliliter of blood, that sensitivity difference is clinically decisive. Published research has demonstrated that digital PCR applied after enrichment culture identifies Bartonella infections that standard qPCR on the same samples consistently missed. For providers evaluating patients with complex or unexplained chronic illness, that is not a marginal improvement. It is often the difference between an answer and another negative result.
Why is it hard to detect Babesia on serology if it lives inside red blood cells?
The intracellular biology of Babesia is part of the challenge, but the more significant issue is technical. To create IFA slides for serological testing, the organism must be cultivated, and because Babesia only propagates inside red blood cells, standard cell lines cannot be used.9,10 This creates a meaningful scientific obstacle for assay development. Compounding this, so little is known about Babesia virulence factors that most assumptions are currently extrapolated from malaria research rather than confirmed directly in Babesia.3-5 Cross-reactivity between species, including Babesia microti, Babesia duncani, and Babesia odocoilei, is also poorly understood, creating both sensitivity and specificity challenges that currently remain unresolved in serological assay development.
Why does Babesia testing produce discordant results?
Different Babesia testing methods measure different biological signals. Serology detects the host immune response (antibodies).12 Molecular methods detect pathogen nucleic acid (DNA).11 Blood smear detects visible parasites within red blood cells.1 A patient can be seropositive and PCR-negative, or PCR-positive and seronegative, because these methods are capturing different aspects of the infection. Discordant results reflect differences in what is being measured, not necessarily conflicting clinical information.
Does a negative Babesia test result rule out the presence of the organism?
Not necessarily. A negative result reflects the testing method’s ability to detect the organism at the time and conditions of sample collection. Parasitemia in chronic Babesia presentations may be low or intermittent, meaning the organism may not be present in detectable quantities in every blood draw. A negative result should always be interpreted within the full clinical context, including symptom history, exposure risk, and the specific diagnostic method used.
What is the difference between qPCR and digital PCR for Babesia detection?
Both qPCR and digital PCR (dPCR) are molecular methods that detect pathogen DNA, but they differ in how they partition and quantify targets. Digital PCR divides the sample into thousands of individual reactions, enabling absolute quantification and improved sensitivity for low-abundance organisms. This can be particularly relevant in chronic Babesia presentations where parasitemia is low and standard qPCR may fall below its detection threshold.
How common is Babesia co-infection with Bartonella or Borrelia?
Babesia, Bartonella, and Borrelia share overlapping vectors, particularly Ixodes scapularis (the blacklegged tick), and co-infection is observed in a meaningful proportion of chronically ill patients.2,6,7,12,16 The clinical significance of co-infection is that symptoms from multiple pathogens overlap and compound, and patients may not respond to approaches targeting only one organism. A comprehensive testing strategy evaluating all three genera simultaneously is more reflective of how these infections present in complex, chronic cases.
References
- Krause PJ, Spielman A, Telford SR, et al. Persistent parasitemia after acute babesiosis. N Engl J Med. 1998;339(3):160-165. doi:10.1056/NEJM199807163390304
- Breitschwerdt EB, Maggi RG, Bush JC, Kingston E. Babesia and Bartonella species DNA in blood and enrichment blood cultures from people with chronic fatigue and concurrent neurological symptoms. Pathogens. 2026;15(1):2. https://doi.org/10.3390/pathogens15010002
- Krause PJ, Daily J, Telford SR, et al. Shared features in the pathobiology of babesiosis and malaria. Trends Parasitol. 2007;23(12):605-610. doi:10.1016/j.pt.2007.09.005
- Djokic V, Rocha SC, Parveen N. Lessons learned for pathogenesis, immunology, and disease of erythrocytic parasites: Plasmodium and Babesia. Front Cell Infect Microbiol. 2021;11:685239. doi:10.3389/fcimb.2021.685239
- Allred DR. Antigenic variation in babesiosis: is there more than one ‘why’?. Microbes Infect. 2001;3(6):481-491. doi:10.1016/s1286-4579(01)01404-6
- Scott JD, Sajid MS, Pascoe EL, Foley JE. Detection of Babesia odocoilei in humans with babesiosis symptoms. Diagnostics (Basel). 2021;11(6):947. doi:10.3390/diagnostics11060947
- Maggi RG, Calchi AC, Moore CO, et al. Human Babesia odocoilei and Bartonella spp. co-infections in the Americas. Parasit Vectors. 2024;17(1):302. doi:10.1186/s13071-024-06385-4
- Shah JS, Mark O, Caoili E, et al. A Fluorescence in Situ Hybridization (FISH) test for diagnosing babesiosis. Diagnostics (Basel). 2020;10(6):377. doi:10.3390/diagnostics10060377
- Schuster FL. Cultivation of Babesia and Babesia-like blood parasites: agents of an emerging zoonotic disease. Clin Microbiol Rev. 2002;15(3):365-373. doi:10.1128/CMR.15.3.365-373.2002
- Hildebrandt A, Zintl A, Montero E, et al. Human babesiosis in Europe. Pathogens. 2021;10(9):1165. doi:10.3390/pathogens10091165
- Maggi RG, Breitschwerdt EB, Qurollo B, Miller JC. Development of a multiplex droplet digital PCR assay for the detection of Babesia, Bartonella, and Borrelia species. Pathogens. 2021;10(11):1462. https://doi.org/10.3390/pathogens10111462\
- Kumar A, O’Bryan J, Krause PJ. The global emergence of human babesiosis. Pathogens. 2021;10(11):1447. doi:10.3390/pathogens10111447
- 60 Degrees Pharmaceuticals survey on babesiosis disease burden in the U.S. https://investors.60degreespharma.com/news-releases/news-release-details/babesiosis-disease-burden-united-states-substantially-higher. Accessed May 29, 2026.
- Centers for Disease Control and Prevention. Data and Statistics on Babesiosis. Updated March 3, 2026. https://www.cdc.gov/babesiosis/php/data-stats/index.html. Accessed May 15, 2026.
- 60 Degrees Pharmaceuticals survey on babesiosis incidence in the U.S. https://investors.60degreespharma.com/news-releases/news-release-details/babesiosis-incidence-us-10x-higher-cdc-estimates-according. Accessed May 29, 2026.
- Scott JD, Scott CM. Molecular detection of Anaplasma phagocytophilum, Babesia odocoilei, and Borrelia burgdorferi sensu lato in Ixodes scapularis ticks collected in veterinary clinics in southern Wellington County, Ontario, Canada. Adv Infect Dis. 16, 253-266. doi: 10.4236/aid.2026.161019.
- Internal report. Data on file. Galaxy Diagnostics, Inc.; 2025.
- Breitschwerdt EB, Maggi RG, Robveille C, Kingston E. Bartonella henselae, Babesia odocoilei and Babesia divergens-like MO-1 infection in the brain of a child with seizures, mycotoxin exposure and suspected Rasmussen’s encephalitis. J Cent Nerv Syst Dis. 2025;17:11795735251322456. doi:10.1177/11795735251322456
- Breitschwerdt EB, Maggi RG, Moore CO, et al. A One Health zoonotic vector borne infectious disease family outbreak investigation. Pathogens. 2025;14(2):110. doi:10.3390/pathogens14020110
About Galaxy Diagnostics
Galaxy Diagnostics provides evidence-driven direct and indirect testing tools for clinicians evaluating complex vector-borne and zoonotic disease cases. The company focuses on diagnostic clarity, scientific precision, and clinical education for providers navigating ambiguous or multi-system presentations.
Explore Galaxy’s testing solutions and clinical education resources.